Mode
Text Size
Log in / Sign up

Molecular markers may improve risk assessment in oral potentially malignant disordersMolecular tools may improve risk assessment for oral lesions

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that histopathological grading alone may miss high-risk OPMDs; molecular markers could refine risk assessment.

This narrative review addresses the clinical challenge of risk stratification for oral potentially malignant disorders (OPMDs), which have an inherent risk of progressing to oral squamous cell carcinoma. The authors critique the limited reliability of conventional histopathological grading, noting that it fails to capture the biological heterogeneity of these lesions. They argue that molecular markers could offer a more precise, individualized risk assessment, aligning with the shift toward molecularly informed medicine. The review does not present pooled data or specific molecular targets but synthesizes conceptual arguments for integrating genomic, proteomic, or epigenetic biomarkers into clinical workflows. Limitations acknowledged include the lack of standardized molecular panels and the need for validation in prospective cohorts. The authors stop short of recommending specific markers, emphasizing that the field is still evolving. For clinicians, the takeaway is that histopathology alone may be insufficient, and future risk assessment will likely incorporate molecular profiling, though routine use is not yet supported by robust evidence.

This narrative review looked at how to manage oral potentially malignant disorders and oral squamous cell carcinoma. The authors noted that standard histopathological grading often lacks reliability. They also pointed out the inherent biological heterogeneity of these lesions makes simple grading difficult. Because of these issues, the review highlights a need for molecularly informed risk assessment in modern healthcare settings. No specific medications or interventions were tested in this review, so no safety data or side effects were reported. The study did not report a specific sample size or follow-up period. Readers should understand that this is a narrative review rather than a clinical trial with new data. The main takeaway is that current grading methods have limits. Doctors might consider molecular tools to help evaluate risk more accurately. This approach could help catch dangerous changes earlier or avoid unnecessary surgery. However, this review does not prove that molecular tests work better. More research is needed to confirm these ideas in real patients.

What this means for you:
Molecular tools might help assess risk for oral lesions where standard grading is unreliable.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Oral potentially malignant disorders (OPMDs) comprise a diverse group of oral mucosal lesions with a variable but significant risk of progression to oral squamous cell carcinoma (OSCC). However, predicting malignant transformation remains a major clinical challenge due to the limited reliability of conventional histopathological grading and the inherent biological heterogeneity of these lesions. Increasing evidence indicates that OPMD progression is a dynamic, multistep process driven by the convergence of molecular alterations and microenvironmental remodeling. This review synthesizes current knowledge on the key mechanisms underlying OPMD-to-OSCC transformation, focusing on the interplay between genomic instability, epigenetic dysregulation, chronic inflammation, and tumor microenvironment evolution. Dysregulation of critical signaling pathways, including TGF-β, PI3K/AKT, MAPK, Wnt/β-catenin, and NF-κB, contributes to epithelial plasticity, immune evasion, fibrosis, and sustained oncogenic signaling. Special attention is given to oral submucous fibrosis as a high-risk model, highlighting the role of extracellular matrix stiffening and mechanotransduction pathways such as YAP/TAZ in promoting malignant progression. The limitations of morphology-based diagnostics underscore the need for molecularly informed risk assessment in modern healthcare. Emerging biomarkers including genetic, epigenetic, transcriptomic, proteomic, metabolomic, and exosomal signatures offer promising tools for early detection and stratification of high-risk lesions. Furthermore, integration of multi-omics data with artificial intelligence based predictive models holds significant potential for advancing precision oncology in oral cancer. Collectively, this review supports an evolutionary shift in understanding OPMDs as dynamic and evolving biological systems rather than static precursor lesions. Elucidating the molecular and microenvironmental convergence driving malignant transformation provides a foundation for improved early detection, risk prediction, and development of targeted preventive and therapeutic strategies in OSCC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.